- Event will feature Aravindhan Veerapandiyan, M.D., principal
investigator of the AFFINITY DUCHENNE® trial
ROCKVILLE, Md., June 2, 2025
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that
it will host a webcast to discuss new interim functional data from
the Phase I/II AFFINITY DUCHENNE® trial of RGX-202,
the company's next-generation investigational gene therapy for the
treatment of Duchenne muscular dystrophy. The webcast will feature
AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan,
M.D., Arkansas Children's Hospital.
Webcast details
Title: AFFINITY
DUCHENNE® Trial of RGX-202: Phase I/II Interim
Functional Data
Date/Time: Thursday, June 5,
2025, at 8:00 a.m. EDT
Access: The live webcast can be accessed here and
in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be
available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology
company on a mission to improve lives through the curative
potential of gene therapy. Since its founding in 2009, REGENXBIO
has pioneered the field of AAV gene therapy. REGENXBIO is advancing
a late-stage pipeline of one-time treatments for rare and retinal
diseases, including RGX-202 for the treatment of Duchenne;
clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and
RGX-111 for the treatment of MPS I, both in partnership with Nippon
Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the
treatment of wet AMD and diabetic retinopathy, in collaboration
with AbbVie. Thousands of patients have been treated with
REGENXBIO's AAV platform, including those receiving Novartis'
ZOLGENSMA®. REGENXBIO's investigational gene therapies have the
potential to change the way healthcare is delivered for millions of
people. For more information, please visit www.REGENXBIO.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-iii-affinity-duchenne-trial-of-rgx-202-302470286.html
SOURCE REGENXBIO Inc.
